TITLE

Eye Infections Linked to Off-Label Avastin Use

PUB. DATE
September 2011
SOURCE
BioWorld Today;9/6/2011, Vol. 22 Issue 172, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on an alert issued by the U.S. Food and Drug Administration (FDA) warning health care professionals that repackaged intravitreal injections of Avastin caused a cluster of serious eye infections in the Miami area.
ACCESSION #
65321011

 

Related Articles

  • H1N1 Flu Effort Applauded.  // Chain Drug Review;2/12/2010, Vol. 32 Issue 4, p72 

    The article reports on the initiative by Food and Drug Administration (FDA) Commissioner Margaret Hamburg to express gratitude to health care professionals for their efforts during the 2009 H1N1 influenza outbreak in the U.S.

  • Avastin Gets More Time for Review.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article accounts on the report issued by the U.S. Food and Drug Administration regarding the extension of the review period for Avastin, a drug used to treat cancer including cancer of the breast, lungs, colon, brain, and kidneys.

  • Medicare to cover expensive cancer treatments.  // PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p11 

    The article reports on the plan of Medicare to cover Avastin bevacizumab for breast cancer treatment regardless of the decision of the U.S. Food and Drug Administration (FDA) to rescind Avastin approval for such indication in July 2011.

  • Most Doctors Back Avastin Withdrawal.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p93 

    The article reports on the support of fifty-eight percent of physicians in a poll by Sermo, on the move of the Food and Drug Administration (FDA) to pull the breast cancer indication for Avastin from the market.

  • News.  // Clinical Infectious Diseases;12/15/2001, Vol. 33 Issue 12, pI 

    Presents updates related to infectious diseases as of of December 2001. Plan of the United States Food and Drug Administration to ban products containing cow brains or spinal tissue; Issue on the nail hygiene of health care practitioners; Eligibility of laboratory workers against the anthrax scare.

  • FDA: beware of 'rogue' wholesale drug distributors.  // AHA News;9/26/2014, Vol. 50 Issue 19, p8 

    The article reports on the program launched by the U.S. Food and Drug Administration (FDA) to educate and warn health care professionals and practice administrators against rogue wholesale drug distributors.

  • New FDA rules may prompt pig Latin drug names. Dolinar, Richard; Brunell, Philip A. // Infectious Diseases in Children;Apr2008, Vol. 21 Issue 4, p44 

    The author offers insights on regulatory changes on naming drugs being issued by the U.S. Food & Drug Administration. He argues that the more guidelines and requirements being placed by the agency on naming drugs, the more confusing and less effective those names become. He says that confusion...

  • Byetta labeling changes.  // Monthly Prescribing Reference;Dec2009, Vol. 25 Issue 12, pA35 

    The article reports on the notification given by the U.S. Food and Drug Administration for healthcare professionals that the Prescribing Information for Byetta has been changed to include information on postmarketing reports of changed kidney function.

  • Second Look -- Advocacy.  // AAOS Now;Mar2011, Vol. 5 Issue 3, p27 

    The article offers news briefs related to orthopaedic surgeons in the U.S. including a study which reveals the defensive imaging orders placed by orthopaedic surgeons, the arrest made by 700 federal agents in nine cities to more than 100 medical personnel due to their allege involvement in false...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics